계피 (카시아)

Trans cinnamaldehyde enhances TRAIL induced apoptosis through ER stress mediated upregulation of DR5 in colorectal cancer cells.

1. Sci Rep. 2025 Nov 6;15(1):38840. doi: 10.1038/s41598-025-20306-0. Trans cinnamaldehyde enhances TRAIL induced apoptosis through ER stress mediated upregulation of DR5 in colorectal cancer cells. Kim DY(1)(2), Kim BG(1)(2), Yun HM(3), Kim OH(3), Kang S(4), Bong JW(4), Lee SI(4), Kim BR(#)(5)(6

The effect of cinnamon supplementation on cardiovascular risk factors in adults: a GRADE assessed systematic review, dose-response and meta-analysis of randomized controlled trials.

1. J Health Popul Nutr. 2025 Jul 3;44(1):233. doi: 10.1186/s41043-025-00967-3. The effect of cinnamon supplementation on cardiovascular risk factors in adults: a GRADE assessed systematic review, dose-response and meta-analysis of randomized controlled trials. Jafari A(1)(2), Mardani H(3), Faghfouri AH(4), AhmadianMoghaddam M(5), Musazadeh V(6)(7), Alaghi A(8)(8). Author information: (1)Student Research Committee, Department of Community Nutrition, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran. (2)Systematic Review and Meta-Analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran. (3)Student Research Committee, Department of Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran. (4)Maternal and Childhood Obesity Research Center, Urmia University of Medical Sciences, Urmia, Iran. (5)Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran. (6)Student Research Committee, Iran University of Medical Sciences, Tehran, Iran. Mosazadeh.vali05@gmail.com. (7)Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. Mosazadeh.vali05@gmail.com. (8)Systematic Review and Meta-Analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran. alirezaalaghi@gmail.com. BACKGROUND: Numerous clinical studies have suggested that cinnamon supplementation may be effective for cardiovascular disease risk factors, but the findings are controversial. This comprehensive systematic review and meta-analysis aimed to assess the impact of cinnamon supplementation on cardiovascular disease risk factors. METHODS: Relevant studies were identified through electronic searches of databases, including Web of Science, PubMed, Central, Scopus, and Embase, up to July 2024. RESULTS: Forty-nine studies were included. Cinnamon supplementation significantly reduced WC (SMD = - 0.40; 95% (CI): - 0.73, - 0.06), DBP (SMD = - 1.04; 95% CI: - 1.54, - 0.55), SBP (SMD = - 0.85; 95% CI: - 1.54, - 0.16), fasting glucose (SMD = - 1.28; 95% CI: - 1.65, - 0.90), fasting insulin (SMD = - 0.26; 95% CI: - 0.50, - 0.02), HbA1c (SMD = - 0.71; 95% CI: - 1.02, - 0.40), HOMA-IR (SMD = - 0.54; 95% CI: - 0.82, - 0.26), postprandial blood glucose (SMD = - 2.28; 95% CI: - 3.48, - 1.08), CRP (SMD = - 0.78; 95% CI: - 1.28, - 0.27), LDL-C (SMD = - 0.71; 95% CI: - 1.02, - 0.40), total cholesterol (TC) (SMD = - 1.15; 95% CI: - 1.55, - 0.75), triglycerides (TG) (SMD = - 0.91; 95% CI: - 1.25, - 0.56), and MDA (SMD = - 0.76; 95% CI: - 1.07, - 0.45). Additionally, cinnamon supplementation significantly elevated HDL-C levels (SMD = 0.56; 95% CI: 0.23, 0.89). CONCLUSION: Cinnamon supplementation demonstrated significant benefits in improving cardiovascular risk factors. These findings suggest its potential as an adjunct therapy for improving cardiovascular disease risk factors. © 2025. The Author(s). DOI: 10.1186/s41043-025-00967-3 PMCID: PMC12224812 PMID: 40611215 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare that they have no conflict of interest.

The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial.

2. Eur J Nutr. 2025 Feb 25;64(2):102. doi: 10.1007/s00394-025-03618-9. The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial. Mansour A(#)(1), Sajjadi-Jazi SM(#)(1), Gerami H(1)(2), Khorasanian AS(1)(3), Moalemzadeh B(4), Karimi S(5), Afrakoti NM(6), Mofid V(7), Mohajeri-Tehrani MR(1), Hekmatdoost A(8). Author information: (1)Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. (2)Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. (3)Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. (4)Department of Internal Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. (5)Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, 46, West Arghavan St., Farahzadi Blvd., Shahrak Gharb, Tehran, Iran. (6)Anesthesiology and Critical Care Department, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. (7)Department of Food Science and Technology, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran. (8)Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, 46, West Arghavan St., Farahzadi Blvd., Shahrak Gharb, Tehran, Iran. a_hekmat2000@yahoo.com. (#)Contributed equally BACKGROUND: Diabetes is a serious global health issue and increases the risk of several chronic diseases. However, if hyperglycemia and other metabolic abnormalities related to diabetes are controlled, fewer micro- and macrovascular complications may occur. OBJECTIVE: To investigate whether daily supplementation with berberine in combination with cinnamon could have effect on cardiometabolic risk factors, such as impaired glucose regulation, dyslipidemia, and hypertension in patients with diabetes. METHODS: Patients with type 2 diabetes were recruited to participate in a parallel, double-blind, placebo-controlled, randomized study. Participants were randomized into berberine in combination with cinnamon supplementation or placebo group. Participants were then asked to take a divided daily dose of 1200 mg berberine and 600 mg cinnamon or placebo for 12 weeks. ANCOVA was then performed to evaluate the differences between the two groups, controlling for the respective baseline values. RESULTS: At the end of study, fasting blood sugar (FBS) (P = 0.031) and hemoglobin A1C (HbA1c) (P = 0.013) were significantly lower in participants taking berberine plus cinnamon than those taking the placebo capsules. The results of the serum lipid profile also indicated a significant difference in the level of low density lipoprotein cholesterol (LDL-C) (P = 0.039), while no difference was observed in the levels of total cholesterol, high density lipoprotein cholesterol (HDL-C), and triglycerides between the study groups. In addition, there was no difference in other measured metabolic and anthropometric parameters between the two groups. CONCLUSION: Twelve weeks of berberine plus cinnamon consumption reduced blood FBS, HbA1c and LDL-C concentration in patients with diabetes. © 2025. Springer-Verlag GmbH Germany, part of Springer Nature. DOI: 10.1007/s00394-025-03618-9 PMID: 39998703 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Consent for publication: Not applicable. Competing interests: It should be emphasized that Dr. Vahid Mofid is an employee of Pajoohesh Gostran Taghzie asan® Company. Other authors have not conflicts of interest or financial ties to disclose.

Effects of Cinnamomum zeylanicum (Ceylon cinnamon) extract on lipid profile, glucose levels and its safety in adults: A randomized, double-blind, controlled trial.

3. PLoS One. 2025 Jan 24;20(1):e0317904. doi: 10.1371/journal.pone.0317904. eCollection 2025. Effects of Cinnamomum zeylanicum (Ceylon cinnamon) extract on lipid profile, glucose levels and its safety in adults: A randomized, double-blind, controlled trial. Muthukuda D(1), de Silva CK(2), Ajanthan S(2), Wijesinghe N(2), Dahanayaka A(2), Pathmeswaran A(3). Author information: (1)Sri Jayawardenepura General Hospital, Nugegoda, Sri Lanka. (2)RemediumOne, Colombo, Sri Lanka. (3)Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka. BACKGROUND: Cinnamon has been studied as a possible way to control blood glucose and serum cholesterol levels. However, there are no well-conducted randomized controlled trials that can accurately measure the lipid and glucose-lowering effects of Cinnamomum zeylanicum (C. zeylanicum) extract. This study primarily aimed to evaluate the effect of a standardized C. zeylanicum extract on serum low-density lipoprotein cholesterol (LDL-C) levels and secondarily on other lipid parameters (high-density lipoprotein cholesterol (HDL-C), total cholesterol and triglycerides), glucose levels, anthropometric measures, blood pressure, and safety outcomes in individuals with an LDL level between 100-190mg/dL. MATERIALS AND METHODS: This was a randomized, double-blinded, placebo-controlled clinical trial. Participants were allocated to either C. zeylanicum extract or placebo group (1:1 allocation ratio). They were advised to take two capsules per day (1000 mg/day, a dose based on prior clinical studies suggesting potential efficacy and safety). Reduction in LDL-C at 12 weeks (from the baseline value) was compared between the two groups using ANCOVA. A complete-case analysis was adhered to in analyzing the outcome data. RESULTS: The mean age (SD) of the 150 participants was 50.4 (10.52) years, and 66% were females. Among the 127 participants assessed at 12 weeks, those in the C. zeylanicum extract arm had a lower LDL-C value than the placebo arm but the difference was not significant (the baseline adjusted mean difference was 6.05mg/dL; 95% CI: -2.43 to 14.52; p = 0.161). However, participants in the C. zeylanicum extract group showed significantly greater reductions in fasting blood sugar (FBS) levels (the baseline adjusted mean difference was 8.59mg/dL; 95% CI: 0.59 to 16.59; p = 0.036). There was a significant interaction effect between the supplement and participants' glycemic status, with individuals with type 2 diabetes mellitus (T2DM) who received C. zeylanicum extract experiencing a notable reduction in FBS levels (standardized coefficient: -63, 95% CI: -102 to -25; p = 0.002). CONCLUSIONS: C. zeylanicum extract did not have significantly reduce LDL-C but demonstrated a significant FBS-lowering effect, particularly in individuals with T2DM, with a favorable safety profile. TRIALS REGISTRATION: The trial was registered with the Sri Lanka Clinical Trials Registry: SLCTR/2021/011. Copyright: © 2025 Muthukuda et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. DOI: 10.1371/journal.pone.0317904 PMCID: PMC11759401 PMID: 39854533 [Indexed for MEDLINE] Conflict of interest statement: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Financial support for this research was provided by SDS Spices Pvt Ltd. This funding covered the costs associated with staff at research sites, including the reimbursement of authors Dimuthu Muthukuda and Arunasalam Pathmeswaran for the time devoted to this study. The authors declare that this funding did not influence the study design, data collection, analysis, interpretation, or the decision to publish these findings. We confirm that our adherence to PLOS ONE policies on sharing data and materials is not altered by the competing interests statement. Further, this does not alter our adherence to PLOS ONE policies on sharing data and materials.

Effects of a supplement associating Lactobacillus strains and proanthocyanidin-rich plant extracts against recurrent uncomplicated, urinary tract infections: A prospective, controlled study.

4. Investig Clin Urol. 2025 Jan;66(1):36-46. doi: 10.4111/icu.20240092. Effects of a supplement associating Lactobacillus strains and proanthocyanidin-rich plant extracts against recurrent uncomplicated, urinary tract infections: A prospective, controlled study. Ait Abdellah S(1), Leblanc A(2), Dauchet Q(2), Blondeau C(2), Bohbot JM(3). Author information: (1)PiLeJe Laboratoire, Paris, France. s.aitabdellah@pileje.com. (2)PiLeJe Laboratoire, Paris, France. (3)Institut Alfred Fournier, Paris, France. PURPOSE: Recurrent cystitis, particularly common in women, substantially diminishes patient quality of life and represents a major clinical practice and public health burden. Increasing development of resistance to antibiotics has encouraged the search for alternative treatments. The benefits of a food supplement associating two Lactobacillus strains with proanthocyanidin A-rich cranberry and cinnamon extracts were evaluated in 80 women with a history of cystitis recurrence. MATERIALS AND METHODS: Post-inclusion recurrence frequency was compared between women taking the investigated supplement daily for 6 months and non-supplemented women, based on patient-completed Acute Cystitis Symptom Score (ACSS) questionnaires. RESULTS: Two-thirds (64.9%) of supplemented women experienced no further episodes of cystitis during the first 6 months of the study compared to only one-third (31.6%) of non-supplemented women (p=0.004), the difference between the two groups being significant from 3 months onward. ACSS scores revealed significantly fewer and less severe urinary symptoms in supplemented women, as well as a significantly reduced impact of these symptoms on quality of life (p<0.0001). CONCLUSIONS: The results shown by extensive data on women suffering from recurrent cystitis, collected over 8 months, indicate that taking the tested supplement daily for 6 months can provide significant benefits in terms of recurrence frequency, symptoms, and quality of life. The study is registered on the ClinicalTrials.gov site under the identifier NCT04987164. © The Korean Urological Association. DOI: 10.4111/icu.20240092 PMCID: PMC11729230 PMID: 39791583 [Indexed for MEDLINE] Conflict of interest statement: Samira Ait Abdellah, Quentin Dauchet, Anne Leblanc, and Claude Blondeau are employees of PiLeJe Laboratoire, but this has made no influence on this work in relation with the company or its products. The other author has nothing to disclose.

Effect of cinnamon supplementation on blood pressure, oxidative stress, and inflammatory biomarkers in adults: An umbrella review of the meta-analyses of randomized controlled trials.

5. Nutr Metab Cardiovasc Dis. 2024 Dec;34(12):2659-2668. doi: 10.1016/j.numecd.2024.08.009. Epub 2024 Aug 24. Effect of cinnamon supplementation on blood pressure, oxidative stress, and inflammatory biomarkers in adults: An umbrella review of the meta-analyses of randomized controlled trials. Zhang K(1), Li Y(2), Lin X(2), Daneshar M(3), Karamian F(3), Li M(4). Author information: (1)Department of Cardiovascular Surgery, Gaozhou People's Hospital, Gaozhou, 525200, China. (2)Department of Cardiovascular Medicine, First Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, 014010, China. (3)Science and Research Branch, School of Nutrition, Islamic Azad University, Tehran, Iran. (4)Department of Pharmacy, Gaozhou People's Hospital, Gaozhou, 525200, China. Electronic address: Doctor0668@163.com. AIMS: Cinnamon has positive effects on markers of cardiometabolic health, including blood pressure (BP), oxidative stress, and inflammation. Despite the evidence accumulated from meta-analysis studies on the effects of cinnamon on these markers, the reported findings are still controversial. This umbrella review was conducted to evaluate the evidence and provide a definitive clarification. DATA SYNTHESIS: We conducted a systematic search in four scientific databases, including PubMed, Scopus, Web of Science, and Embase electronic databases, up to March 2024 to identify systematic reviews and meta-analyses of randomized clinical trials investigating the impact of cinnamon on blood pressure, oxidative stress, and inflammation. The findings revealed that cinnamon might exert favorable effects on systolic blood pressure (SBP) (ES = -2.36 mmHg; 95% CI: 3.86, -1.40), diastolic blood pressure (DBP) (ES = -1.65 mmHg; 95% CI: 2.41, -0.90), total antioxidant capacity (TAC) (WMD = 0.34; 95% CI: 0.04, 0.64), and interleukin-6 (IL-6) (WMD = -1.48; 95% CI: 2.96, -0.01). However, the results did not show any significant effect of cinnamon on malondialdehyde (MDA) (WMD = -0.47; 95% CI: 0.99, 0.05), C-reactive protein (CRP) (WMD = -1.33; 95% CI: 2.66, 0.00), and intercellular adhesion molecule 1 (ICAM-1) (WMD= 1.53, 95% CI: 12.03, 15.10). CONCLUSIONS: The results of the studies included in this umbrella review support the usefulness of cinnamon consumption in modulating BP as well as improving TAC and IL-6 in metabolic disorders. Due to the limited number of studies, clinical diversity, and other limitations, more high-quality studies must be conducted to provide more precise and comprehensive recommendations. REGISTRATION NUMBER: PROSPERO, CRD42023487350. Copyright © 2024 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved. DOI: 10.1016/j.numecd.2024.08.009 PMID: 39299867 [Indexed for MEDLINE] Conflict of interest statement: Declaration of competing interest There is no conflict of interest to declare.

Effects of cinnamon supplementation on metabolic biomarkers in individuals with type 2 diabetes: a systematic review and meta-analysis.

6. Nutr Rev. 2025 Feb 1;83(2):249-279. doi: 10.1093/nutrit/nuae058. Effects of cinnamon supplementation on metabolic biomarkers in individuals with type 2 diabetes: a systematic review and meta-analysis. de Moura SL(1), Gomes BGR(1), Guilarducci MJ(2), Coelho OGL(3), Guimarães NS(4), Gomes JMG(1). Author information: (1)Federal Institute of Education, Science and Technology of the Southeast of Minas Gerais-Campus Barbacena-IF Sudeste MG, Barbacena, MG, 36.205-018, Brazil. (2)School of Public Health, University of São Paulo-FSP/USP, São Paulo, SP, 01.246-904, Brazil. (3)Federal University of Viçosa-Campus Viçosa-UFV, Viçosa, MG, 36.570-900, Brazil. (4)Department of Nutrition, Federal University of Minas Gerais School of Nursing, Belo Horizonte, MG, 30.130-100, Brazil. CONTEXT: The global prevalence of type 2 diabetes mellitus (DM2) has been rising significantly over the years. Recent studies have shown beneficial effects of cinnamon on metabolic biomarkers. OBJECTIVE: The objective of this review was to assess the effect of cinnamon supplementation on metabolic biomarkers in patients with DM2. DATA SOURCES: The Pubmed/MEDLINE, Cochrane CENTRAL, and Embase databases were searched up to November 10, 2022. DATA EXTRACTION: A systematic search was performed for randomized controlled trials (RCTs) evaluating the effect of cinnamon supplementation on metabolic biomarkers, in adults and the elderly with DM2, and comparing the data for a cinnamon intervention group with that for a placebo group or a control group. The main exclusion criteria were studies (1) with other types of diabetes (ie, gestational diabetes or type 1 diabetes), (2) without cinnamon consumption, (3) that did not evaluate metabolic biomarkers, or (4) in vitro and animal studies. Two researchers independently screened 924 records, evaluated full-text studies, extracted data, and appraised their quality. A third researcher was consulted to resolve any discrepancies. The data were pooled using random-effects models and expressed as the weighted mean difference (WMD) with 95% CI. Heterogeneity was assessed using Cochran's Q test and quantified using I2 statistics. Risk of bias was assessed using the Joanna Briggs Institute (JBI) instrument. Sensitivity analysis and the GRADE system were used to assess the robustness and certainty of the findings. DATA ANALYSIS: In total, 28 RCTs with a duration ranging from 30 to 120 days and a total enrollment of 3054 patients with DM2 were included. Participants consuming cinnamon showed a significant reduction in fasting blood glucose (FBG) (WMD: -15.26 mg/dL; 95% CI: -22.23 to -8.30; I2 = 88%), postprandial glucose (WMD: -39.22 mg/dL; 95% CI: -63.90 to -14.55; I2 = 100%), HbA1c (WMD: -0.56 mg/dL; 95% CI: -0.99 to -0.13; I2 = 94%), and HOMA-IR (WMD = -0.76, 95% CI: -1.13 to -0.39; I2 = 22%) compared with the control group. An intervention of cinnamon in capsule form reduced FBG (WMD:-18.43 mg/dL, 95% CI: -26.32 to -10.53; I2 = 89%), postprandial glucose (WMD: -44.83 mg/dL, 95% CI: -70.67 to -18.99; I2 = 100%), HbA1c (WMD: -0.56 mg/dL, 95% CI: -1.02 to -0.09; I2 = 94%), total cholesterol (WMD: -13.39 mg/dL; 95% CI: -24.71 to -2.07; I2 = 96%), LDL-C (WMD: -6.49 mg/dL, 95% CI: -12.69 to -0.29; I2 = 92%), and triglycerides (WND: -19.75 mg/dL; 95% CI, -33.71 to -5.80; I2 = 88%). Both doses (≤2 g/day and >2 g/day) reduced FBG and postprandial glucose. Only cinnamon doses of ≤2 g/day reduced HbA1c (WMD: -0.68 mg/dL, 95% CI: -1.16 to -0.1; I2 = 92%), HOMA-IR (WMD: -0.94 mg/dL; 95% CI: -1.21 to -0.67; I2 = 0%), and BMI (WMD: -1.18 kg/m2; 95% CI: -1.97 to -0.39; I2 = 0%). CONCLUSION: The data suggest that cinnamon improves the glycemic and lipid profile and reduces the BMI, particularly in DM2 patients who receive cinnamon supplementation in capsule form and at a dose of ≤2 g/day. SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration no. CRD42022370332. © The Author(s) 2024. Published by Oxford University Press on behalf of the International Life Sciences Institute. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. DOI: 10.1093/nutrit/nuae058 PMID: 38917435 [Indexed for MEDLINE]

The Effect of Therapeutic Doses of Culinary Spices in Metabolic Syndrome: A Randomized Controlled Trial.

7. Nutrients. 2024 May 29;16(11):1685. doi: 10.3390/nu16111685. The Effect of Therapeutic Doses of Culinary Spices in Metabolic Syndrome: A Randomized Controlled Trial. Al Dhaheri AS(1), Alkhatib DH(1), Feehan J(2), Cheikh Ismail L(3)(4), Apostolopoulos V(2)(5), Stojanovska L(1)(2). Author information: (1)Department of Nutrition & Health Sciences, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates. (2)Institute for Health and Sport, Victoria University, Melbourne, VIC 8001, Australia. (3)Department of Clinical Nutrition and Dietetics, College of Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates. (4)Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford OX1 2JD, UK. (5)Immunology Program, Australian Institute of Musculoskeletal Science (AIMSS), Melbourne, VIC 3021, Australia. Erratum in Nutrients. 2024 Nov 05;16(22):3791. doi: 10.3390/nu16223791. Non-communicable diseases (NCDs) place a significant burden on global health and the healthcare systems which support it. Metabolic syndrome is a major risk factor for a large number of NCDs; however, treatments remain limited. Previous research has shown the protective benefits of edible dietary spices on key components of metabolic syndrome. Therefore we performed a 12-week double-blind, placebo-controlled, randomized, clinical trial to evaluate the effect of ginger (Zingiber officinale), cinnamon (Cinnamomum), and black seed (Nigella sativa) consumption on blood glucose, lipid profiles, and body composition in 120 participants with, or at risk of, metabolic syndrome. Each participant consumed 3 g/day of powder (spice or placebo). Data related to different parameters were collected from participants at the baseline, midpoint, and endpoint of the intervention. Over the 12-week interventions, there was an improvement in a number of biochemical indices of metabolic syndrome, including fasting blood glucose, HbA1c, LCL, and total cholesterol associated with supplementation with the spices when compared to a placebo. This study provides evidence to support the adjunct use of supplementation for those at risk of metabolic syndrome and its sequelae. DOI: 10.3390/nu16111685 PMCID: PMC11175078 PMID: 38892617 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflict of interest.

Effect of cinnamon spice on continuously monitored glycemic response in adults with prediabetes: a 4-week randomized controlled crossover trial.

8. Am J Clin Nutr. 2024 Mar;119(3):649-657. doi: 10.1016/j.ajcnut.2024.01.008. Epub 2024 Jan 26. Effect of cinnamon spice on continuously monitored glycemic response in adults with prediabetes: a 4-week randomized controlled crossover trial. Zelicha H(1), Yang J(2), Henning SM(2), Huang J(2), Lee RP(2), Thames G(2), Livingston EH(1), Heber D(2), Li Z(3). Author information: (1)Department of Surgery, University of California, Los Angeles, Los Angeles, CA, United States. (2)Department of Medicine, Center for Human Nutrition, David Geffen School of Medicine, Los Angeles, United States. (3)Department of Medicine, Center for Human Nutrition, David Geffen School of Medicine, Los Angeles, United States. Electronic address: zli@mednet.ucla.edu. BACKGROUND: Previous clinical studies showing that cinnamon spice lowers blood glucose concentrations had inconsistent results. OBJECTIVES: To determine the effect of daily cinnamon spice supplementation in an amount commonly used for seasoning on glucose concentrations in adults with obesity and prediabetes. METHODS: Following a 2-wk run-in period of maintaining a low polyphenol/fiber diet, 18 participants with obesity and prediabetes underwent a 10-wk randomized, controlled, double-blind, crossover trial (mean age 51.1 y; mean fasting plasma glucose 102.9 mg/dL). The participants were randomly assigned to take cinnamon (4 g/d) or placebo for 4-wk, followed by a 2-wk washout period, and then crossed over to the other intervention for an additional 4-wk. Glucose changes were measured with continuous glucose monitoring. Oral glucose tolerance testing immediately following ingestion of cinnamon or placebo was performed at 4-time points to assess their acute effects both at the baseline and end of each intervention phase. Digestive symptom logs were obtained daily. RESULTS: There were 694 follow-up days with 66,624 glucose observations. When compared with placebo, 24-h glucose concentrations were significantly lower when cinnamon was administered [mixed-models; effect size (ES) = 0.96; 95 % confidence interval (CI): -2.9, -1.5; P < 0.001]. Similarly, the mean net-area-under-the-curve (netAUC) for glucose was significantly lower than for placebo when cinnamon was given (over 24 h; ES = -0.66; 95 % CI: 2501.7, 5412.1, P = 0.01). Cinnamon supplementation resulted in lower glucose peaks compared with placebo (Δpeak 9.56 ± 9.1 mg/dL compared with 11.73 ± 8.0 mg/dL; ES = -0.57; 95 % CI: 0.8, 3.7, P = 0.027). Glucose-dependent-insulinotropic-polypeptide concentrations increased during oral glucose tolerance testing + cinnamon testing (mixed-models; ES = 0.51; 95 % CI: 1.56, 100.1, P = 0.04), whereas triglyceride concentrations decreased (mixed-models; ES = 0.55; 95 % CI: -16.0, -1.6, P = 0.02). Treatment adherence was excellent in both groups (cinnamon: 97.6 ± 3.4 % compared with placebo: 97.9 ± 3.7 %; ES = -0.15; 95 % CI: -1.8, 0.2, P = 0.5). No differences were found in digestive symptoms (abdominal pain, borborygmi, bloating, excess flatus, and stools/day) between cinnamon and placebo groups. CONCLUSIONS: Cinnamon, a widely available and low-cost supplement, may contribute to better glucose control when added to the diet in people who have obesity-related prediabetes. This trial was registered at clinicaltrials.gov as NCT04342624. Published by Elsevier Inc. DOI: 10.1016/j.ajcnut.2024.01.008 PMID: 38290699 [Indexed for MEDLINE]

Effectiveness of a Food Supplement Based on Glucomannan, D-Chiro-Inositol, Cinnamomum zeylanicum Blume and Inulin in Patients with Metabolic Syndrome.

9. Nutrients. 2024 Jan 12;16(2):249. doi: 10.3390/nu16020249. Effectiveness of a Food Supplement Based on Glucomannan, D-Chiro-Inositol, Cinnamomum zeylanicum Blume and Inulin in Patients with Metabolic Syndrome. Citarrella R(1), Chianetta R(1), Amodeo S(1), Mirarchi L(2), Licata A(1), Soresi M(1), Veronese N(1), Barbagallo M(1), Giannitrapani L(1)(3). Author information: (1)Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy. (2)Department of Internal Medicine, National Relevance and High Specialization Hospital Trust ARNAS Civico, Di Cristina, Benfratelli, 90127 Palermo, Italy. (3)Institute for Biomedical Research and Innovation (IRIB), National Research Council, 90146 Palermo, Italy. Metabolic syndrome (MetS) is associated with cardiovascular risk factors, such as insulin resistance, dyslipidaemia, hypertension and abdominal obesity. Given the growing need to investigate food supplements with positive health effects, this study was aimed at testing the benefits of a specific supplement for people with MetS. Fifty-eight subjects with MetS and T2DM or impaired glucose tolerance assuming metformin, were randomly assigned to take a food supplement of glucomannan, D-chiro-inositol, Cinnamomum zeylanicum blume and inulin at a daily fixed dose of 4 g orally for four months. Body weight, waist circumference, plasma lipid profile (total cholesterol, LDL, HDL and triglyc-erides), plasma glycaemic profile and visceral adiposity index (VAI) were measured at baseline and after four months of supplementation. After 16 weeks, in subjects with T2DM or insulin resistance who took the supplement (+ metformin), there was a significant reduction in body weight and BMI (p < 0.0001), serum insulin (p < 0.05) and the HOMA index (p < 0.01), as well as in the lipaemic pattern, with a significant improvement in total serum cholesterol (p < 0.005), triglycerides (p < 0.03) and LDL (p < 0.02). Our study shows that the food supplement tested is a valid and safe alternative therapeutic approach in the management of MetS and all its resulting risk factors, as its efficacy has been demonstrated across anthropometric, glucose, lipid and hepatic parameters. DOI: 10.3390/nu16020249 PMCID: PMC10819678 PMID: 38257142 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflict of interest.

The effect of cinnamon supplementation on glycemic control in patients with type 2 diabetes mellitus: An updated systematic review and dose-response meta-analysis of randomized controlled trials.

10. Phytother Res. 2024 Jan;38(1):117-130. doi: 10.1002/ptr.8026. Epub 2023 Oct 11. The effect of cinnamon supplementation on glycemic control in patients with type 2 diabetes mellitus: An updated systematic review and dose-response meta-analysis of randomized controlled trials. Moridpour AH(1), Kavyani Z(1)(2), Khosravi S(3), Farmani E(4), Daneshvar M(4), Musazadeh V(1)(2), Faghfouri AH(5). Author information: (1)Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. (2)School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. (3)Department of Medicine, Tehran University of Medical Sciences, Tehran, Iran. (4)Tehran University of Medical Sciences, Tehran, Iran. (5)Maternal and Childhood Obesity Research Center, Urmia University of Medical Sciences, Urmia, Iran. Although many randomized controlled trials (RCTs) have revealed the benefits of cinnamon on type 2 diabetes mellitus (T2DM), the effects of cinnamon supplementation on glycemic control in patients with T2DM are inconclusive. Therefore, the aim of this meta-analysis of RCTs was to assess the effects of cinnamon supplementation in managing glycemic control in patients with T2DM. Scientific international databases including Scopus, Web of Sciences, PubMed, Embase, and the Cochrane Library were searched till December 2022. For net changes in glycemic control, standard mean differences (SMDs) were calculated using random-effects models. Findings from 24 RCTs revealed that cinnamon supplementation had a statistically significant reduction in fasting blood sugar (SMD: -1.32; 95% CI: -1.77, -0.87, p < 0.001), Homeostatic Model Assessment for Insulin Resistance (SMD: -1.32; 95% CI: -1.77, -0.87, p < 0.001), and hemoglobin A1C (SMD: -0.67; 95% CI: -1.18, -0.15, p = 0.011) compared with the control group in patients with T2DM. Additionally, cinnamon did not change the serum levels of insulin (SMD: -0.17; 95% CI: -0.34, 0.01, p = 0.058) significantly. Our analysis indicated that glycemic control indicators are significantly decreased by cinnamon supplementation. Together, these findings support the notion that cinnamon supplementation might have clinical potential as an adjunct therapy for managing T2DM. © 2023 John Wiley & Sons Ltd. DOI: 10.1002/ptr.8026 PMID: 37818728 [Indexed for MEDLINE]

The effect of cinnamon consumption on lipid profile, oxidative stress, and inflammation biomarkers in adults: An umbrella meta-analysis of randomized controlled trials.

11. Nutr Metab Cardiovasc Dis. 2023 Oct;33(10):1821-1835. doi: 10.1016/j.numecd.2023.03.010. Epub 2023 Mar 18. The effect of cinnamon consumption on lipid profile, oxidative stress, and inflammation biomarkers in adults: An umbrella meta-analysis of randomized controlled trials. Sarmadi B(1), Musazadeh V(2), Dehghan P(3), Karimi E(4). Author information: (1)Department of Nutrition Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia. (2)Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: mosazadeh.vali05@gmail.com. (3)Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: dehghan.nut@gmail.com. (4)Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. AIMS: Cinnamon is a polyphenol-rich spice that has beneficial effects on markers of cardio metabolic health such as lipid profile, oxidative stress, and inflammation. Despite the accumulating evidence from meta-analyses on the effects of cinnamon on these markers, their findings are controversial. Thus, this umbrella meta-analysis was performed to evaluate the present evidence and provide a conclusive clarification. DATA SYNTHESIS: We searched the following international databases from inception to January 2022: PubMed, Scopus, Web of Science and Embase, and Google Scholar. Our findings of eleven meta-analyses showed that cinnamon consumption can significantly improve total cholesterol (TC) (WMD = -1.01 mg/dL; 95% CI: -2.02, -0.00, p = 0.049), low-density lipoprotein-cholesterol (LDL-C) (WMD = -0.82 mg/dL; 95% CI: -1.57, -0.07, p = 0.032), and high-density lipoprotein-cholesterol (HDL-C) (WMD = 0.47 mg/dL; 95% CI: 0.17, 0.77, p = 0.002) levels but not triglyceride (TG) levels (WMD = -0.13 mg/dL; 95% CI: -0.58, 0.32, p = 0.570). Our results did not show any significant effect of cinnamon on malondialdehyde (MDA) levels (WMD = -0.47; 95% CI: -0.99, 0.05, p = 0.078) and C-reactive protein (CRP) levels (WMD = -1.33; 95% CI: -2.66, 0.00, p = 0.051) but there was enhanced total antioxidant capacity (TAC) in patients with type 2 diabetes (T2DM) and polycystic ovary syndrome (PCOS) (WMD = 0.34; 95% CI: 0.04, 0.64, p = 0.026) and increased levels of interleukin-6 (WMD = -1.48; 95% CI: -2.96, -0.01, p = 0.049). CONCLUSIONS: Our results support the usefulness of cinnamon intake in modulating an imbalanced lipid profile in some metabolic disorders, particularly PCOS, as well as in improving TAC and interleukin-6. The review protocol was registered on PROSPERO as CRD42022358827. Copyright © 2023 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved. DOI: 10.1016/j.numecd.2023.03.010 PMID: 37500345 [Indexed for MEDLINE] Conflict of interest statement: Declaration of competing interest There is no conflict of interest to declare.

Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers.

12. J Am Coll Cardiol. 2023 Jan 3;81(1):1-12. doi: 10.1016/j.jacc.2022.10.013. Epub 2022 Nov 6. Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers. Laffin LJ(1), Bruemmer D(1), Garcia M(2), Brennan DM(2), McErlean E(2), Jacoby DS(3), Michos ED(4), Ridker PM(5), Wang TY(6), Watson KE(7), Hutchinson HG(8), Nissen SE(9). Author information: (1)Cleveland Clinic Foundation, Cleveland, Ohio, USA. (2)C5 Research, Cleveland Clinic Foundation, Cleveland, Ohio, USA. (3)University of Pennsylvania, Philadelphia, Pennsylvania, USA. (4)Johns Hopkins, Baltimore, Maryland, USA. (5)Brigham and Women's Hospital, Boston, Massachusetts, USA. (6)Duke University, Durham, North Carolina, USA. (7)University of California-Los Angeles, Los Angeles, California, USA. (8)AstraZeneca BioPharmaceuticals, Wilmington, Delaware, USA. (9)Cleveland Clinic Foundation, Cleveland, Ohio, USA; C5 Research, Cleveland Clinic Foundation, Cleveland, Ohio, USA. Electronic address: nissens@ccf.org. Comment in Nat Rev Cardiol. 2023 Jan;20(1):6. doi: 10.1038/s41569-022-00809-3. J Am Coll Cardiol. 2023 Jan 3;81(1):13-15. doi: 10.1016/j.jacc.2022.11.004. MMW Fortschr Med. 2023 Feb;165(3):73. doi: 10.1007/s15006-023-2359-4. J Am Coll Cardiol. 2023 May 2;81(17):e149. doi: 10.1016/j.jacc.2023.01.048. J Am Coll Cardiol. 2023 May 2;81(17):e151. doi: 10.1016/j.jacc.2023.02.046. BACKGROUND: Supplements are commonly used by individuals with indications for lipid-lowering therapy, but evidence of their effectiveness to lower low-density lipoprotein cholesterol (LDL-C) is lacking, particularly when compared with statins. OBJECTIVES: The trial objective was to compare the efficacy of a low-dose statin with placebo and 6 common supplements in impacting lipid and inflammatory biomarkers. METHODS: This was a single-center, prospective, randomized, single-blind clinical trial among adults with no history of atherosclerotic cardiovascular disease (ASCVD), an LDL-C of 70 to 189 mg/dL, and an increased 10-year risk of ASCVD. Participants were randomized to rosuvastatin 5 mg daily, placebo, fish oil, cinnamon, garlic, turmeric, plant sterols, or red yeast rice. The primary endpoint was the percent change in LDL-C from baseline for rosuvastatin 5 mg daily compared with placebo and each supplement after 28 days. The primary endpoint was evaluated in a hierarchical fashion with rosuvastatin first compared with placebo, then each supplement in a prespecified order using analysis of covariance. RESULTS: A total of 190 participants completed the study. The percent LDL-C reduction with rosuvastatin was greater than all supplements and placebo (P < 0.001). The difference in LDL-C reduction with rosuvastatin compared with placebo was -35.2% (95% CI: -41.3% to -29.1%; P < 0.001). None of the dietary supplements demonstrated a significant decrease in LDL-C compared with placebo. Adverse event rates were similar across study groups. CONCLUSIONS: Among individuals with increased 10-year risk for ASCVD, rosuvastatin 5 mg daily lowered LDL-C significantly more than placebo, fish oil, cinnamon, garlic, turmeric, plant sterols, and red yeast rice. (Supplements, Placebo, or Rosuvastatin Study [SPORT]; NCT04846231). Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. DOI: 10.1016/j.jacc.2022.10.013 PMID: 36351465 [Indexed for MEDLINE] Conflict of interest statement: Funding Support and Author Disclosures This trial was funded by AstraZeneca Pharmaceuticals. Dr Laffin has been a consultant and/or served on steering committees for Medtronic, Lilly, Mineralys Therapeutics, AstraZeneca, and Crispr Therapeutics; has received research funding from AstraZeneca; and has ownership interest in LucidAct Health and Gordy Health. Dr Bruemmer has been a consultant and served on a steering committee for Esperion. Dr Jacoby has been a consultant and served on a steering committee for AstraZeneca. Dr Michos has been a consultant and/or served on steering committees for AstraZeneca, Bayer, Boehringer Ingelheim, Esperion, Novartis, Novo Nordisk, and Pfizer; and has received research funding from the American Heart Association and the National Institutes of Health. Dr Ridker has been a consultant and/or served on steering committees for Agepha, AstraZeneca, Civi Biopharm, Flame Inc, Health Outlook, IQVIA, Janssen Pharmaceuticals, Novartis, Novo Nordisk, Omeicos, and Sirnanomics; and has received research funding from Amarin, Kowa Pharmaceuticals, the National Heart, Lung, and Blood Institute, and Novartis. Dr Wang has been a consultant and/or served on steering committees for AstraZeneca and Novartis; and has received research funding from Abbott Laboratories, Artivion, Boston Scientific, Bristol Myers Squibb, and Chiesi. Dr Watson has been a consultant and/or served on steering committees for Amari, Amgen, Boehringer Ingelheim, Esperion, Novartis, and Lilly; and has been a speaker for Boehringer Ingelheim. Dr Hutchinson is an employee of AstraZeneca. Dr Nissen has received institutional research funding from AbbVie, AstraZeneca, Amgen, Bristol Myers Squibb, Cerenis, Eli Lilly, Esperion, Medtronic, MyoKardia, Novartis, Pfizer, The Medicines Company, Silence Therapeutics, Takeda, and Orexigen; and is an unpaid consultant for Respira, Alnylam, Beren Therapeutics, Prolaio, TenSixteen Bio, Altimmune, MetroBiotech, and Intercept. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

What is the influence of cinnamon supplementation on liver enzymes? A systematic review and meta-analysis of randomized controlled trials.

13. Phytother Res. 2021 Oct;35(10):5634-5646. doi: 10.1002/ptr.7200. Epub 2021 Jul 1. What is the influence of cinnamon supplementation on liver enzymes? A systematic review and meta-analysis of randomized controlled trials. Mousavi SM(1), Jayedi A(2), Bagheri A(1), Zargarzadeh N(3), Wong A(4), Persad E(5), Akhgarjand C(6), Koohdani F(7). Author information: (1)Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. (2)Food Safety Research Center (salt), Semnan University of Medical Sciences, Semnan, Iran. (3)School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. (4)Department of Health and Human Performance, Marymount University, Arlington, Virginia, USA. (5)Department for Evidence-based Medicine and Evaluation, Danube University Krems, Krems, Austria. (6)Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. (7)Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. Existing evidence has uncovered the potential health benefits of cinnamon intake; however, its effect on liver function is unclear. Thus, the aim of this systematic review and meta-analysis was to examine the effect of cinnamon supplementation on liver enzymes. Relevant articles were identified through a systematic search in PubMed/Medline, Scopus, Web of Science, Cochrane Library, and Embase up to September 2020. All trials assessing the effect of oral cinnamon supplementation on serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) in adults were included. The pooled effect sizes were obtained using the random-effects model and expressed as mean difference (MD) and 95% confidence intervals (CI). A total of seven original trials (nine treatment arms) involving a total of 256 subjects were included in the final analysis. The pooled analysis indicated that cinnamon supplementation had no significant effect on serum levels of ALT, AST, and ALP. However, there was a significant reduction in ALT levels in patients with type 2 diabetes (MD: -4.01 U/L; 95% CI: -6.86, -1.15) and in trials with low-dose supplementation (<1,500 mg/d), follow-up duration longer than 12 weeks, and in the elderly patients (aged>50 years). The beneficial effects of cinnamon intake were also shown in AST levels in patients with type 2 diabetes and trials with long-term follow-up (>12 weeks). Longer-term, oral cinnamon supplementation may improve serum levels of liver enzymes in patients with type 2 diabetes. Further high-quality studies are needed, especially in populations with abnormal liver enzyme levels, to firmly establish the clinical efficacy of cinnamon on liver function. © 2021 John Wiley & Sons Ltd. DOI: 10.1002/ptr.7200 PMID: 34212447 [Indexed for MEDLINE]

The beneficial effects of cinnamon among patients with metabolic diseases: A systematic review and dose-response meta-analysis of randomized-controlled trials.

14. Crit Rev Food Sci Nutr. 2022;62(22):6113-6131. doi: 10.1080/10408398.2021.1896473. Epub 2021 Mar 19. The beneficial effects of cinnamon among patients with metabolic diseases: A systematic review and dose-response meta-analysis of randomized-controlled trials. Kutbi EH(1), Sohouli MH(2)(3), Fatahi S(2)(3), Lari A(2), Shidfar F(2), Aljhdali MM(4), Alhoshan FM(5), Elahi SS(6), Almusa HA(7), Abu-Zaid A(8)(9). Author information: (1)Biomedical Research Administration, Biorepository Department, King Fahad Medical City, Riyadh, Saudi Arabia. (2)Student Research Committee, Faculty of Public Health Branch, Iran University of Medical Sciences, Tehran, Iran. (3)Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. (4)Department of Internal Medicine, King Fahad General Hospital, Jeddah, Saudi Arabia. (5)College of Medicine, Ibn Sina National College for Medical Studies, Jeddah, Saudi Arabia. (6)College of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. (7)Department of Respiratory Care, Dr. Sulaiman Al Habib Hospital, Riyadh, Saudi Arabia. (8)College of Medicine, Alfaisal University, Riyadh, Saudi Arabia. (9)College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA. This systematic review and meta-analysis aims to summarize and conclude the clinical evidence regarding the use of cinnamon among patients with metabolic diseases. A comprehensive literature search without any limitation on language was conducted using the following bibliographical databases: ISI Web of Science, Embase, Scopus, PubMed, and Google Scholar. Search was conducted up to 23 January 2020. A total of 35 clinical trials were included for final analysis. Pooling of results showed a significant reducing effect of cinnamon on total cholesterol (TC) (weighted mean difference (WMD) = -11.67 mg/dL; P = 0.010), triglyceride (TG) (WMD = -16.27 mg/dL; P < 0.001), low density lipoprotein-cholesterol (LDL-C) (WMD = -6.36 mg/dL; P < 0.001), serum glucose (WMD = -11.39 mg/dL; P < 0.001), serum insulin (WMD = -1.27 μIU/mL; P = 0.028), and waist circumstance (WC) (WMD = -1.68 cm; P = 0.016). These lowering effects on TG, TC, LDL-C, and serum glucose levels were robust in studies that used cinnamon supplementation dose ≤1.5 g. Also, our findings of the present meta-analysis showed that cinnamon supplementation could have favorable effects on high density lipoprotein-cholesterol (HDL-C, WMD = 1.35; P = 0.038) as well as systolic (WMD = -3.95 mmHg; P = 0.018) and diastolic (WMD = -3.36; P = 0.001) blood pressure among patients with metabolic diseases. The present meta-analysis suggests that cinnamon might exert beneficial effects on various cardiometabolic risk factors among patients with metabolic diseases. DOI: 10.1080/10408398.2021.1896473 PMID: 33739219 [Indexed for MEDLINE]

The effect of cinnamon supplementation on liver enzymes in adults: A systematic review and meta-analysis of randomized controlled trials.

15. Complement Ther Med. 2021 May;58:102699. doi: 10.1016/j.ctim.2021.102699. Epub 2021 Feb 24. The effect of cinnamon supplementation on liver enzymes in adults: A systematic review and meta-analysis of randomized controlled trials. Shekarchizadeh-Esfahani P(1), Heydarpour F(2), Izadi F(3), Jalili C(4). Author information: (1)Department of General Courses, School of Management and Medical Information Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. (2)Social Development and Health Promotion Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. (3)Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran. (4)Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. Electronic address: cjalili@yahoo.com. AIMS: The aim of this study was to perform a systematic review and meta-analysis of randomized controlled trials (RCTs) to examine the effect of cinnamon supplementation on liver enzymes. METHODS: A systematic search was performed in electronic databases including PubMed-Medline, Scopus, and ISI Web of Science up to November 2020. We used a random effects model to estimate pooled effect size of alanine aminotransferase (ALT), alkaline phosphatase (ALP), and aspartate aminotransferase (AST) levels. RESULTS: Seven RCTs (9 treatment arms) fulfilled the eligibility criteria of the present meta-analysis. Overall, meta-analysis could not show any beneficial effect of cinnamon supplementation on AST, ALT, and ALP. Subgroup analyses showed that the effect of cinnamon supplementation on ALT was significant at the dosages of <1500 mg/day (Hedges's: -0.61; 95 % CI: -1.11, -0.10; P = 0.002), in trials lasting>12 weeks (Hedges's: -0.83; 95 % CI: -1.36, -0.30; P = 0.01), and in trials conducted of both gender (Hedges's: -0.72; 95 % CI: -1.45, -0.01; P = 0.04). CONCLUSION: In summary, cinnamon supplementation had no significant effect on liver enzymes in adults. However, the effect of cinnamon on ALT levels was significant at the dosages of <1500 mg/day, in trials lasting>12 weeks, and in trials conducted of both gender. Nevertheless, further studies should be performed to confirm our results. Copyright © 2021. Published by Elsevier Ltd. DOI: 10.1016/j.ctim.2021.102699 PMID: 33639251 [Indexed for MEDLINE]